Oversight of Biomedical Technologies: What Can We Learn from Past Efforts?

Thursday, March 6, 2008 - 12:30pm to 2:00pm

Theater, Coffman Memorial Union

Tremendous controversy surrounds the question of how to exercise effective oversight over cutting-edge biomedical technologies. At the federal level, past efforts have included presidentially appointed panels, NIH and FDA expert committees, and calls for legislation. Self-regulation by professional societies and litigation have also played a role. A participant in a number of the federal efforts, including the Human Embryo Research Panel, Prof. King reflected on what has worked and what has not, and what the lessons can be learned for future oversight. 


R. Scott McIvor, PhD
Department of Genetics, Cell Biology and Development
University of Minnesota

Rep. Phyllis Kahn, PhD, MPA
District 59B, Minnesota House of Representatives

Continuing legal education credit (CLE) for attorneys (1.5 hours) was approved. 

Patricia A. King, JD, is the Carmack Waterhouse Professor of Law, Medicine, Ethics, and Public Policy at Georgetown University and adjunct professor in the Department of Health Policy and Management, School of Hygiene and Public Health at Johns Hopkins University.

Prof. King's expertise is in the study of law, medicine, ethics and public policy. She is the co-author of Cases and Materials on Law, Science and Medicine. She is a member of the American Law Institute and the Institute of Medicine and a Fellow of the Hastings Center.

Prof. King's work in the field of bioethics has included service on the HEW-Advisory Recombinant DNA Advisory Committee, the President's Commission for the Study of Ethical Problems in Medicine and Biomedical and Behavioral Research, the National Commission for the Protection of Human Subjects of Biomedical and Behavioral Research, and the Ethics, Legal and Social Issues Working Group of the Human Genome Project. She is a fellow of the Harvard Corporation and a member of the Board of Trustees of Wheaton College.

March 6, 2008